Cellular accumulation of anandamide: Consensus and controversy

British Journal of Pharmacology

Volumn 140, Issue 5, 2003, Pages 802-808

  Hillard, Cecilia J ^a   Jarrahian, Abbas ^a,b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b BUTLER UNIVERSITY   (United States)

Author keywords

2 Arachidonylglycerol; AM404; Cannabinoid; Endocannabinoid; Fatty acid amide hydrolase; N arachidonylethanolamine; Noladin ether; Virodhamine

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 4 AMINOPYRIDINE; ANANDAMIDE; BENZYLSULFONYL FLUORIDE; CALCIUM IONOPHORE; CANNABINOID RECEPTOR ANTAGONIST; CARRIER PROTEIN; ENZYME INHIBITOR; ESTRADIOL; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; IONOMYCIN; MEMBRANE PROTEIN; METHYLARACHIDONYL FLUOROPHOSPHONATE; N (3 FURYLMETHYL)ARACHIDONAMIDE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; O 2109; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHLORIDE; RIMONABANT; SODIUM CHANNEL STIMULATING AGENT; U 2109; UNCLASSIFIED DRUG; VERATRIDINE;

BIOACCUMULATION; CALCIUM CELL LEVEL; CATABOLISM; CELL LEVEL; CELL MEMBRANE POTENTIAL; CELL MEMBRANE TRANSPORT; CONCENTRATION (PARAMETERS); HUMAN; ISOTOPE LABELING; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SHORT SURVEY; TRANSPORT KINETICS;

ANIMALS; ARACHIDONIC ACIDS; BIOLOGICAL TRANSPORT; CELL MEMBRANE; HUMANS; POLYUNSATURATED ALKAMIDES; VERATRIDINE;

EID: 0344441315     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705468     Document Type: Short Survey

References (54)

1. BASAVARAJAPPA, B.S., SAITO, M., COOPER, T.B. & HUNGUND, B.L. (2003). Chronic ethanol inhibits the anandamide transport and increases extracellular anandamide levels in cerebellar granule neurons. Eur. J. Pharmacol., 466, 73-83.
2. BELTRAMO, M., DE FONSECA, F.R., NAVARRO, M., CALIGNANO, A., GORRITI, M.A., GRAMMATIKOPOULOS, G., SADILE, A.G., GIUFFRIDA, A. & PIOMELLI D. (2000). Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor. J. Neurosci., 20, 3401-3407.
3. BELTRAMO, M. & PIOMELLI, D. (2000). Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol. Neuroreport, 11, 1231-1235.
4. BELTRAMO, M., STELLA, N., CALIGNANO, A., LIN, S.Y., MAKRIYANNIS, A. & PIOMELLI, D. (1997). Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science, 277, 1094-1097.
5. BISOGNO, T., MACCARRONE, M., DE PETROCELLIS, L., JARRAHIAN, A., FINAZZI-AGRO, A., HILLARD, C. & DI MARZO, V. (2001). The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors. Eur. J. Biochem., 268, 1982-1989.
6. BISOGNO, T., MAURELLI, S., MELCK, D., DE PETROCELLIS, L. & DI MARZO, V. (1997). Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J. Biol. Chem., 272, 3315-3323.
7. CALIGNANO, A., LA RANA, G., BELTRAMO, M., MAKRIYANNIS, A. & PIOMELLI, D. (1997). Potentiation of anandamide hypotension by the transport inhibitor, AM404. Eur. J. Pharmacol., 337, R1-R2.
8. CRAVATT, B.F., GIANG, D.K., MAYFIELD, S.P., BOGER, D.L., LERNER, R.A. & GILULA, N.B. (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature, 384, 83-87.
9. DAY, T.A., RAKHSHAN, F., DEUTSCH, D.G. & BARKER, E.L. (2001). Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide. Mol. Pharmacol., 59, 1369-1375.
10. DE PETROCELLIS, L., BISOGNO, T., DAVIS, J.B., PERTWEE, R.G. & DI MARZO, V. (2000). Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett., 483, 52-56.
11. DEUTSCH, D. & CHIN, S. (1993). Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem. Pharmacol., 46, 791-796.
12. DEUTSCH, D.G., GLASER, S.T., HOWELL, J.M., KUNZ, J.S., PUFFENBARGER, R.A., HILLARD, C.J. & ABUMRAD, N. (2001). The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide hydrolase. J. Biol. Chem., 276, 6967-6973.
13. DEUTSCH, D.G., OMEIR, R., ARREAZA, G., SALEHANI, D., PRESTWICH, G.D., HUANG, Z. & HOWLETT, A. (1997). Methyl arachidonyl fluorophosphonate: a potent irreversible inhibitor of anandamide amidase. Biochem. Pharmacol., 53, 255-260.
14. DEVANE, W.A., HANUS, L., BREUER, A., PERTWEE, R.G., STEVENSON, L.A., GRIFFIN, G., GIBSON, D., MANDELBAUM, A., ETINGER, A. & MECHOULAM, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 1946-1949.
15. DI MARZO, V., BISOGNO, T., MELCK, D., ROSS, R., BROCKIE, H., STEVENSON, L., PERTWEE, R. & DE PETROCELLIS, L. (1998). Interactions between synthetic vanilloids and the endogenous cannabinoid system. FEES Lett., 436, 449-454.
16. DI MARZO, V., FONTANA, A., CADAS, H., SCHINELLI, S., CIMINO, G., SCHWARTZ, J.C. & PIOMELLI, D. (1994). Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature, 372, 686-691.
17. DI MARZO, V., GRIFFIN, G., DE PETROCELLIS, L., BRANDI L BISOGNO, T., WILLIAMS, W., GRIER, M.C., KULASEGRAM, S., MAHADEVAN, A., RAZDAN, R.K. & MARTIN, B.R. (2002). A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid. J. Pharmacol. Exp. Ther., 300, 984-991.
18. DINH, T.P., CARPENTER, D., LESLIE, P.M., FREUND, T.F., KATONA, I., SENSI, S.L., KATHURIA, S. & PIOMELLI, D. (2002). Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. U.S.A., 99, 10819-10824.
19. FEZZA, F., BISOGNO, T., MINASSI, A., APPENDINO, G., MECHOULAM, R. & DI MARZO, V. (2002). Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett., 513, 294-298.
20. FREUND, T.F., KATONA, I. & PIOMELLI, D. (2003). Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev., 83, 1017-1066.
21. GERDEMAN, G.L., RONESI, J. & LOVINGER, D.M. (2002). Post-synaptic endocannabinoid release is critical to long-term depression in the striatum. Nat. Neurosci., 5, 446-451.
22. GIUFFRIDA, A., BELTRAMO, M. & PIOMELLI, D. (2001). Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J. Pharmacol. Exp. Ther., 298, 7-14.
23. GIUFFRIDA, A., RODRIGUEZ DE FONSECA, F., NAVA, F., LOUBET-LESCOULIE, P. & PIOMELLI, D. (2000). Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404. Eur. J. Pharmacol., 408, 161-168.
24. GLASER, S.T., ABUMRAD, N.A., FATADE, F., KACZOCHA, M., STUDHOLME, K.M. & DEUTSCH, D.G. (2003). Evidence against the presence of an anandamide transporter. Proc. Natl. Acad. Sci. U.S.A., 100, 4269-4274.
25. GONZALEZ, S., ROMERO, J., DE MIGUEL, R., LASTRES-BECKER, I., VILLANUA, M.A., MAKRIYANNIS, A., RAMOS, J.A. & FERNANDEZ-RUIZ, J.J. (1999). Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide. Life Sci., 65, 327-336.
26. GUBELLINI, P., PICCONI, B., BARI, M., BATTISTA, N., CALABRESI, P., CENTONZE, D., BERNARDI, G., FINAZZI-AGRO, A. & MACCARRONE, M. (2002). Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J. Neurosci., 22, 6900-6907.
27. HANUS, L., ABU-LAFI, S., FRIDE, E., BREUER, A., VOGEL, Z., SHALEV, D.E., KUSTANOVICH, I. & MECHOULAM, R. (2001). 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. U.S.A., 98, 3662-3665.
28. HILLARD, C.J. (2000). Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol. Prostagtandins Lipid Mediat., 61, 3-18.
29. HILLARD, C.J., EDGEMOND, W.S., JARRAHIAN, A. & CAMPBELL, W.B. (1997). Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. J. Neurochem., 69, 631-638.
30. HILLARD, C.J. & JARRAHIAN, A. (2000). The movement of N-arachidonoylethanolamine (anandamide) across cellular membranes. Chem. Phys. Lipids. 108, 123-134.
31. HILLARD, C.J., WILKISON, D.M., EDGEMOND, W.S. & CAMPBELL, W.B. (1995). Characterization of the kinetics and distribution of N-arachidonylethanolamine (anandamide) hydrolysis by rat brain. Biochim. Biophys. Acta, 1257, 249-256.
32. JARRAHIAN, A., MANNA, S., EDGEMOND, W.S., CAMPBELL, W.B. & HILLARD, C.J. (2000). Structure-activity relationships among N-arachidonylethanolamine (Anandamide) head group analogues for the anandamide transporter. J. Neurochem., 74, 2597-2606.
33. KATHURIA, S., GAETANI, S., FEGLEY, D., VALINO, F., DURANTI, A., TONTINI, A., MOR, M., TARZIA, G., LA RANA, G., CALIGNANO, A., GIUSTINO, A., TATTOLI, M., PALMERY, M., CUOMO, V. & PIOMELLI, D. (2003). Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med., 9, 76-81.
34. LICHTMAN, A.H., HAWKINS, E.G., GRIFFIN, G. & CRAVATT, B.F. (2002). Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. J. Pharmacol. Exp. Ther., 302, 73-79.
35. LOPEZ-RODRIGUEZ, M.L., VISO, A., ORTEGA-GUTIERREZ, S., FOWLER, C.J., TIGER, G., DE LAGO, E., FERNANDEZ-RUIZ, J. & RAMOS, J.A. (2003a). Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors. Eur. J. Med. Chem., 38, 403-412.
36. LOPEZ-RODRIGUEZ, M.L., VISO, A., ORTEGA-GUTIERREZ, S., FOWLER, C.J., TIGER, G., DE LAGO, E., FERNANDEZ-RUIZ, J. & RAMOS, J.A. (2003b). Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase. J. Med. Chem., 46, 1512-1522.
37. MACCARRONE, M., ATTINA, M., BARI, M., CARTONI, A., LEDENT, C. & FINAZZI-AGRO, A. (2001). Anandamide degradation and N-acylethanolamines level in wild-type and CB(1) cannabinoid receptor knockout mice of different ages. J. Neurochem., 78, 339-348.
38. MACCARRONE, M., BARI, M., BATTISTA, N. & FINAZZI-AGRO, A. (2002). Estrogen stimulates arachidonoylethanolamide release from human endothelial cells and platelet activation. Blood. 100, 4040-4048.
39. MACCARRONE, M., BARI, M., LORENZON, T., BISOGNO, T., DI MARZO, V. & FINAZZI-AGRO, A. (2000a). Anandamide uptake by human endothelial cells and its regulation by nitric oxide. J. Biol. Chem., 275, 13484-13492.
40. MACCARRONE, M., FIORUCCI, L., ERBA, F., BARI, M., FINAZZI-AGRO, A. & ASCOLI, F. (2000b). Human mast cells take up and hydrolyze anandamide under the control of 5-lipoxygenase and do not express cannabinoid receptors. FEBS Lett., 468, 176-180.
41. MACCARRONE, M., FIORUCCI, L., ERBA, F., BARI, M., FINAZZI-AGRO, A. & ASCOLI, F. (2000c). Human mast cells take up and hydrolyze anandamide under the control of 5-lipoxygenase and do not express cannabinoid receptors. FEBS Lett., 468, 176-180.
42. MACCARRONE, M., VAN DER STELT, M., ROSSI, A., VELDINK, G.A., VLIEGENTHART, J.F. & AGRO, A.F. (1998). Anandamide hydrolysis by human cells in culture and brain. J. Biol. Chem., 273, 32332-32339.
43. MATSUDA, L.A., LOLAIT, S.J., BROWNSTEIN, M.J., YOUNG, A.C. & BONNER, T.I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346, 561-564.
44. MCFARLAND, M.J., PORTER, A.C. & BARKER, E.L. (2003). Uptake of the endogenous cannabinoid anandamide by endocytic processes and accumulation in lipid rafts. Exp. Biol., 2003. (Abstract 395.9).
45. MUTHIAN, S., NITHIPATIKOM, K., CAMPBELL, W.B. & HILLARD, C.J. (2000). Synthesis and characterization of a fluorescent substrate for the N-arachidonoylethanolamine (anandamide) transmembrane carrier. J. Pharmacol, Exp. Ther., 293, 289-295.
46. PIOMELLI, D., BELTRAMO, M., GLASNAPP, S., LIN, S.Y., GOUTOPOULOS, A., XIE, X.Q. & MAKRIYANNIS, A. (1999). Structural determinants for recognition and translocation by the anandamide transporter. Proc. Natl. Acad. Sci., 96, 5802-5807.
47. PORTER, A.C., SAUER, J.M., KNIERMAN, M.D., BECKER, G.W., BERNA, M.J., BAO, J., NOMIKOS, G.G., CARTER, P., BYMASTER, F.P., LEESE, A.B. & FELDER, C.C. (2002). Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J. Pharmacol. Exp. Ther., 301, 1020-1024.
48. RAKHSHAN, F., DAY, T.A., BLAKELY, R.D. & BARKER, E.L. (2000). Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells. J. Pharmacol. Exp. Ther., 292, 960-967.
49. SCHMID, H.H. (2000). Pathways and mechanisms of N-acylethanolamine biosynthesis: can anandamide be generated selectively? Chem. Phys. Lipids, 108, 71-87.
50. STREMMEL, W., POHL, L., RING, A. & HERRMANN, T. (2001). A new concept of cellular uptake and intracellular trafficking of long-chain fatty acids. Lipids, 36, 981-989.
51. SUGIURA, T., KONDO, S., SUKAGAWA, A., NAKANE, S., SHINODA, A., ITOH, K., YAMASHITA, A. & WAKU, K. (1995). 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun., 215, 89-97.
52. SUGIURA, T. & WAKU, K. (2000). 2-Arachidonoylglycerol and the cannabinoid receptors. Chem Phys Lipids, 108, 89-106.
53. UEDA, N., PUFFENBARGER, R.A., YAMAMOTO, S. & DEUTSCH, D.O. (2000). The fatty acid amide hydrolase (FAAH). Chem. Phys. Lipids, 108, 107-121.
54. ZYGMUNT, P.M., CHUANG, H., MOVAHED, P., JULIUS, D. & HOGESTATT, E.D. (2000). The anandamide transport inhibitor AM404 activates vanilloid receptors. Eur. J. Pharmacol., 396, 39-42.